146 related articles for article (PubMed ID: 37715634)
1.
Ragoonanan D; Nickelsen P; Tran N; Allen B; Emborski R; Legare A; Villela A; Hampson L; Busey K; Shomo E; Broomfield A; Hailu K
J Intensive Care Med; 2024 Apr; 39(4):306-312. PubMed ID: 37715634
[TBL] [Abstract][Full Text] [Related]
2. Timing of vasopressin initiation and mortality in patients with septic shock: analysis of the MIMIC-III and MIMIC-IV databases.
Xu J; Cai H; Zheng X
BMC Infect Dis; 2023 Apr; 23(1):199. PubMed ID: 37013474
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic Instability Secondary to Vasopressin Withdrawal in Septic Shock.
Bissell BD; Magee C; Moran P; Bastin MLT; Flannery AH
J Intensive Care Med; 2019 Sep; 34(9):761-765. PubMed ID: 28750598
[TBL] [Abstract][Full Text] [Related]
4. Effect of early vasopressin combined with norepinephrine on short-term mortality in septic shock: A retrospective study based on the MIMIC-IV database.
He D; Zhang L; Hu H; Gu WJ; Lu X; Qiu M; Li C; Yin H; Lyu J
Am J Emerg Med; 2023 Jul; 69():188-194. PubMed ID: 37167890
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Vasopressor Discontinuation Strategies in Patients With Septic Shock on Concomitant Norepinephrine and Vasopressin Infusions.
Musallam N; Altshuler D; Merchan C; Zakhary B; Aberle C; Papadopoulos J
Ann Pharmacother; 2018 Aug; 52(8):733-739. PubMed ID: 29560736
[TBL] [Abstract][Full Text] [Related]
6. Timing of Vasopressin Addition to Norepinephrine and Efficacy Outcomes in Patients With Septic Shock.
Brask AL; Shemanski SM; Barnes TE; Holmes AK
Ann Pharmacother; 2023 May; 57(5):521-526. PubMed ID: 36039490
[TBL] [Abstract][Full Text] [Related]
7. Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series Analysis.
Bauer SR; Sacha GL; Reddy AJ
Ann Pharmacother; 2020 Apr; 54(4):314-321. PubMed ID: 31679395
[No Abstract] [Full Text] [Related]
8. Efficacy and Safety of Vasopressin as First-Line Treatment of Distributive and Hemorrhagic Shock States.
Haan BJ; Cadiz ML; Natavio AM
Ann Pharmacother; 2020 Mar; 54(3):213-218. PubMed ID: 31625395
[No Abstract] [Full Text] [Related]
9. Efficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock.
Wu JY; Stollings JL; Wheeler AP; Semler MW; Rice TW
Ann Pharmacother; 2017 Jan; 51(1):13-20. PubMed ID: 27630192
[TBL] [Abstract][Full Text] [Related]
10. Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock.
Anantasit N; Boyd JH; Walley KR; Russell JA
Crit Care Med; 2014 Aug; 42(8):1812-20. PubMed ID: 24919159
[TBL] [Abstract][Full Text] [Related]
11. Vasopressor Discontinuation Order in Septic Shock With Reduced Left Ventricular Function.
Taylor A; Jones T; Forehand CC; Smith SE; Dykes H; Newsome AS
J Pharm Pract; 2022 Dec; 35(6):879-885. PubMed ID: 33977793
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Early Versus Late Initiation of Hydrocortisone in Patients With Septic Shock in the ICU Setting.
Ragoonanan D; Allen B; Cannon C; Rottman-Pietrzak K; Bello A
Ann Pharmacother; 2022 Mar; 56(3):264-270. PubMed ID: 34109850
[TBL] [Abstract][Full Text] [Related]
13. Norepinephrine and Vasopressin Compared With Norepinephrine and Epinephrine in Adults With Septic Shock.
Menich BE; Miano TA; Patel GP; Hammond DA
Ann Pharmacother; 2019 Sep; 53(9):877-885. PubMed ID: 30957512
[No Abstract] [Full Text] [Related]
14. Influence of Timing and Catecholamine Requirements on Vasopressin Responsiveness in Critically ill Patients with Septic Shock.
Jakowenko ND; Murata J; Kopp BJ; Erstad BL
J Intensive Care Med; 2022 Nov; 37(11):1512-1519. PubMed ID: 35195486
[No Abstract] [Full Text] [Related]
15. Discontinuation of Vasopressin Before Norepinephrine in the Recovery Phase of Septic Shock.
Hammond DA; McCain K; Painter JT; Clem OA; Cullen J; Brotherton AL; Chopra D; Meena N
J Intensive Care Med; 2019 Oct; 34(10):805-810. PubMed ID: 28618919
[TBL] [Abstract][Full Text] [Related]
16. Hydrocortisone versus vasopressin for the management of adult patients with septic shock refractory to norepinephrine: A multicenter retrospective study.
Kulesza S; Gignac L; Colvin CA; Boll S; Giuliano C; Haan B; Allen B; Perez MM; Allen M; Edwin SB
Pharmacotherapy; 2023 Aug; 43(8):787-794. PubMed ID: 37148191
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of the Early Addition of Vasopressin to Norepinephrine in Septic Shock.
Hammond DA; Cullen J; Painter JT; McCain K; Clem OA; Brotherton AL; Chopra D; Meena N
J Intensive Care Med; 2019; 34(11-12):910-916. PubMed ID: 28820036
[TBL] [Abstract][Full Text] [Related]
18. Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock.
Sacha GL; Lam SW; Duggal A; Torbic H; Reddy AJ; Bauer SR
Pharmacotherapy; 2018 Mar; 38(3):319-326. PubMed ID: 29328496
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Early Versus Late Adjunctive Vasopressin and Corticosteroids in Patients With Septic Shock.
Alshehri AM; Kovacevic MP; Dube KM; Lupi KE; DeGrado JR
Ann Pharmacother; 2024 May; 58(5):461-468. PubMed ID: 37542417
[TBL] [Abstract][Full Text] [Related]
20. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.
Gordon AC; Mason AJ; Thirunavukkarasu N; Perkins GD; Cecconi M; Cepkova M; Pogson DG; Aya HD; Anjum A; Frazier GJ; Santhakumaran S; Ashby D; Brett SJ;
JAMA; 2016 Aug; 316(5):509-18. PubMed ID: 27483065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
